
    
      Two vaccine candidates will be used in two different prime-boost regimens: ADVAX (DNA) +
      TBC-M4 (MVA) and TBC-M4 (MVA) alone. Both these vaccines have already been tested in humans
      and both were found to be well tolerated and immunogenic. Approximately 32 volunteers (24
      vaccine /8 placebo recipients) will be included in the study.
    
  